Aerovate Therapeutics
A clinical stage biopharmaceutical company developing drugs that target rare cardiopulmonary disease.
Aerovate's initial focus is on advancing AV-101, its proprietary dry powder inhaled formulation of the antiproliferative drug imatinib. Developed specifically for pulmonary arterial hypertension (PAH), AV-101 targets cellular hyperproliferation and resistance to apoptosis, driven by improper signaling in cells of the distal pulmonary arteries.
As of June 2024, Aerovate has approximately $100 million of cash, cash equivalents and short-term investments.
Latest Aerovate Therapeutics News & Features
18 June 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze